Zhang Jing, Zhang Jiawen, Zhao Weiwei, Li Qingxian, Cheng Wenwu
Department of Integrated Therapy, Shanghai Cancer Center, Fudan University, Shanghai, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Front Genet. 2023 Jan 9;13:1067826. doi: 10.3389/fgene.2022.1067826. eCollection 2022.
Nuclear receptor NR1H3 is a key regulator of macrophage function and lipid homeostasis. Here, we aimed to visualize the prognostic value and immunological characterization of NR1H3 in breast cancer. The expression pattern and prognostic value of NR1H3 were analyzed via multiple databases, including TIMER2, GEPIA2 and Kaplan-Meier Plotter. TISIDB, TIMER2 and immunohistochemical analysis were used to investigate the correlation between NR1H3 expression and immune infiltration. GO enrichment analysis, KEGG analysis, Reactome analysis, ConsensusPathDB and GeneMANIA were used to visualize the functional enrichment of NR1H3 and signaling pathways related to NR1H3. We demonstrated that the expression of NR1H3 was significantly lower in breast cancer compared with adjacent normal tissues. Kaplan-Meier survival curves showed shorter overall survival in basal breast cancer patients with low NR1H3 expression, and poorer prognosis of relapse-free survival in breast cancer patients with low NR1H3 expression. NR1H3 was mainly expressed in immune cells, and its expression was closely related with infiltrating levels of tumor-infiltrating immune cells in breast cancer. Additionally, univariate and multivariate analysis indicated that the expression of NR1H3 and the level of macrophage infiltration were independent prognostic factors for breast cancer. Gene interaction network analysis showed the function of NR1H3 involved in regulating of innate immune response and macrophage activation. Moreover, NR1H3 may function as a predictor of chemoresponsiveness in breast cancer. These findings suggest that NR1H3 serves as a prognostic biomarker and contributes to the regulation of macrophage activation in breast cancer.
核受体NR1H3是巨噬细胞功能和脂质稳态的关键调节因子。在此,我们旨在阐明NR1H3在乳腺癌中的预后价值和免疫特征。通过多个数据库,包括TIMER2、GEPIA2和Kaplan-Meier Plotter,分析了NR1H3的表达模式和预后价值。利用TISIDB、TIMER2和免疫组织化学分析来研究NR1H3表达与免疫浸润之间的相关性。采用GO富集分析、KEGG分析、Reactome分析、ConsensusPathDB和GeneMANIA来可视化NR1H3的功能富集以及与NR1H3相关的信号通路。我们证明,与相邻正常组织相比,乳腺癌中NR1H3的表达显著降低。Kaplan-Meier生存曲线显示,NR1H3表达低的基底型乳腺癌患者总生存期较短,NR1H3表达低的乳腺癌患者无复发生存期预后较差。NR1H3主要在免疫细胞中表达,其表达与乳腺癌中肿瘤浸润免疫细胞的浸润水平密切相关。此外,单因素和多因素分析表明,NR1H3的表达和巨噬细胞浸润水平是乳腺癌的独立预后因素。基因相互作用网络分析显示NR1H3的功能涉及调节先天免疫反应和巨噬细胞激活。此外,NR1H3可能作为乳腺癌化疗反应性的预测指标。这些发现表明,NR1H3作为一种预后生物标志物,有助于调节乳腺癌中的巨噬细胞激活。